Artios Pharma Ltd, a developer of cancer drugs, has appointed Ian Smith as chief medical officer to oversee the development of its portfolio of drugs that target DNA repair mechanisms. Dr Smith joins from Eli Lilly and Co where he was a senior medical director. Prior to this he was responsible for the development of lead oncology drugs at AstraZeneca Plc. Before joining the pharmaceutical industry, Dr Smith spent 10 years in clinical-academic training in oncology and radiology at the University of Aberdeen, UK, where he obtained his bachelor degree in medicine and surgery.
Artios Pharma announced the appointment on 1 April 2019.
Copyright 2019 Evernow Publishing